REJOICE-Ovarian01
Tests whether a CDH6-targeting ADC with Enhertu's payload can beat chemotherapy in resistant ovarian cancer.
The phase 2 dose-optimisation part reported an objective response rate of 50.5% (ESMO 2025); the phase 3 part randomises at 5.6 mg/kg against chemotherapy. Readout expected 2026-27.
Setting
Platinum-resistant ovarian cancer, 1-3 prior lines: raludotatug deruxtecan (CDH6 ADC) vs physician's-choice chemotherapy
Phase
Phase 2/3
Sponsor
Daiichi Sankyo / Merck
Registry
Headline result
Phase 2 ORR 50.5%; phase 3 ongoing.
In plain words
What these results mean for people, not percentages
Objective response rate (phase 2 part)response endpoint
- 50.5 out of 100 people had their tumour shrink with R-DXd.
- There was no comparison group, so this number cannot tell you how much of the effect is due to the treatment.
- A response rate counts how many people had their tumours shrink by a set amount; shrinking is encouraging but does not by itself show that people live longer or feel better.
- These results apply to the people the trial enrolled: Platinum-resistant ovarian cancer, 1-3 prior lines: raludotatug deruxtecan (CDH6 ADC) vs physician's-choice chemotherapy. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Pages like this
not linked directly; found by shared links- TermTetrapeptide GGFG (maleimide-GGFG-aminomethyl)
Shares Raludotatug deruxtecan, Antibody-drug conjugate (ADC).
- CompanyTubulis (Gilead)
- PersonKan Yonemori
- TrialRAINFOL-01 (Rina-S)
- ProductPuxitatug samrotecan
- TrialMIRASOL / GOG-3045
- CompanyMersana Therapeutics
- ProductLuveltamab tazevibulin